Desipramine for Improving Cellular Signaling and Decreasing Symptoms of Major Depression

• Status: Completed
• Trial end date: 1993-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will determine the effectiveness of desipramine in improving cellular signaling, and thereby decreasing symptoms of depression in people with major depressive disorder (MDD).

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Harvard Medical School; Harvard Medical School (HMS and HSDM)
• Collaborator: National Institute of Mental Health (NIMH)
• Treatments: Desipramine

Criteria

Inclusion Criteria:

• Clinical diagnosis of MDD (as defined by SCID [DSM III-R] and a score of at least 15 on the 21-item Hamilton Depression Scale)

• Able to swallow tablets, give urine and blood samples, and participate in periodic evaluations during the study

• Healthy volunteers show no current Axis I or Axis II disorders and score less than 8 on the Hamilton Depression Scale

Exclusion Criteria:

• Use of any of the following medications within the 2 weeks prior to study entry:

psychoactive medication; aspirin; or nonsteroidal anti-inflammatory agents

• Any alcohol or drug abuse within the 6 months prior to study entry

• Any major medical disorder